AMD Ryan Initiative Study (ARIS)
NCT03092492 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 26
Last updated 2026-04-01
Summary
Objective:
To learn more about AMD.
Eligibility:
People ages 55 and older with any of the following:
Early AMD
RPD
Healthy eyes
Design:
Participants will be screened with:
Eye exam: The pupil will be dilated with eye drops. Eye pressure and movements will be checked. Pictures will be taken of the inside of the eye.
Reading an eye chart.
Optical coherence tomography (OCT): The eyes are dilated. A machine measures the thickness of the retina.
Participants will have a first visit that includes:
Repeat of screening procedures
Medical history
Physical exam
Questions about vision and general health
Dark adapted fundus perimetry: Participants sit in the dark for 40 minutes. Then they sit at a machine that shines lights in the eyes.
Dark adaption testing: Participants sit in the dark for 45 minutes. The pupils are dilated. They push a button when they see light in a machine for up to 1 hour.
Participants will have annual visits for up to 5 years to repeat the tests in the first visit. Participant data may be shared for other research....
Conditions
- Age-Related Macular Degeneration
Sponsors & Collaborators
-
National Eye Institute (NEI)
lead NIH
Principal Investigators
-
Emily Y Chew, M.D. · National Eye Institute (NEI)
Eligibility
- Min Age
- 55 Years
- Max Age
- 120 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-02-12
- Primary Completion
- 2022-04-11
- Completion
- 2022-04-11
Countries
- United States
Study Locations
More Related Trials
-
Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)
NCT01397409 ·Status: COMPLETED ·Phase: PHASE2
-
A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe
NCT05569148 ·Status: COMPLETED ·Phase: PHASE3
-
RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration
NCT04895293 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration
NCT01255462 ·Status: COMPLETED ·Phase: PHASE1
-
Genetic Study of Age-Related Macular Degeneration
NCT00357578 ·Status: COMPLETED
-
AGN-151597 (Formerly RST-001) Phase I/II Trial for Advanced Retinitis Pigmentosa
NCT02556736 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)
NCT01339949 ·Status: WITHDRAWN ·Phase: NA
-
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
NCT06795048 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Evaluation of the Association Between Genetic Load and Response to Anti-VEGF Therapy in AMD Patients
NCT01644513 ·Status: COMPLETED
-
A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration
NCT04640272 ·Status: COMPLETED ·Phase: PHASE2
-
Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration
NCT00877032 ·Status: COMPLETED ·Phase: PHASE1
-
Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye
NCT02581891 ·Status: COMPLETED ·Phase: PHASE4
-
Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
NCT05803785 ·Status: RECRUITING ·Phase: PHASE1
-
Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD)
NCT01301443 ·Status: COMPLETED ·Phase: PHASE1
-
Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement
NCT03531294 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
NCT00090532 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration
NCT02022501 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
NCT03999801 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2
-
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
NCT05210803 ·Status: ENROLLING_BY_INVITATION
-
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
NCT03178149 ·Status: RECRUITING ·Phase: PHASE1
-
Safety Study of rAAV2/8-hCYP4V2 in Patients With Bietti's Crystalline Dystrophy (BCD)
NCT04722107 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia
NCT04403763 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma
NCT06223048 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema
NCT03622593 ·Status: COMPLETED ·Phase: PHASE3
-
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT05769153 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2